---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014610"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:51:30.161541+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DiaMedica files clinical hold response; Q1 cash $28.7M; Phase 1C confirms DM199 dose safety

## Summary
- Company will file complete clinical hold response to FDA this week for ReMEDy2 AIS trial; in-use study supports dose revision to 0.5 µg/kg IV.
- Phase 1C SAD study in healthy volunteers affirms revised DM199 IV dose is well-tolerated and achieves therapeutic blood levels.
- Cash, cash equivalents and investments $28.7M as of March 31, 2023; working capital $26.9M; cash runway into Q4 2024.
- R&D expenses $3.6M in Q1 2023, up 80% YoY, driven by clinical hold studies and team expansion; G&A $1.9M, up 19%.
- Post-quarter $0.75M private investment from newly appointed Chief Business Officer; net cash used in ops $5.1M in Q1.

## SEC filing metadata
- accession: 0001437749-23-014610
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/0001437749-23-014610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/dmtp20230512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014610
- JSON: https://secwatch.observer/filing/0001437749-23-014610.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014610.txt

## Key facts
- Earnings Releases
  DiaMedica Therapeutics Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/0001437749-23-014610-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.